[Translation] A single-center, double-blind, parallel, single-dose comparative study evaluating the safety of nimodipine injection concentrate in healthy study participants.
以北京德立福瑞医药科技有限公司研制、生产的尼莫地平注射用浓溶液(规格:1 mL:10 mg)为受试制剂,以Bayer Vital GmbH持证的尼莫地平注射液(商品名:尼膜同®,规格:50 mL:10 mg)为对照制剂,在健康研究参与者中进行单中心、双盲、平行、单次给药的人体安全性对比研究。本研究旨在考察尼莫地平注射用浓溶液在健康成年人中单次连续静脉滴注给药的安全性,验证本品相比市售制剂尼膜同®注射液在安全性方面具有优势,同时未带来新的安全性风险。
[Translation] This study investigated the safety of nimodipine concentrated injection solution (1 mL:10 mg), developed and manufactured by Beijing Delifure Pharmaceutical Technology Co., Ltd., as the test formulation, and nimodipine injection solution (trade name: Nimodipine®, 50 mL:10 mg), licensed by Bayer Vital GmbH, as the control formulation. The aim was to conduct a single-center, double-blind, parallel, single-dose human safety comparison study in healthy adults.